What the FDA labels say about taking them together
Ketoconazole and paricalcitol
Paricalcitol's FDA label of August 7, 2024 names ketoconazole in its drug interactions section; the ketoconazole label PlainMeds reads does not name paricalcitol. The paricalcitol label: “DRUG INTERACTIONS Co-administration with strong CYP3A inhibitors (e.g. ketoconazole) increases paricalcitol blood levels.”
Check it at the source: the ketoconazole FDA label on DailyMed (effective January 28, 2026, E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC); the paricalcitol FDA label on DailyMed (effective August 7, 2024, AbbVie Inc.).
What does the ketoconazole label say about paricalcitol?
Ketoconazole's label (effective January 28, 2026) does not name paricalcitol in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ketoconazole), E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, effective January 28, 2026 (SPL set cad7c647-34a9-4e4e-83b3-8d78e58f588f), via openFDA; the full label on DailyMed
What does the paricalcitol label say about ketoconazole?
Paricalcitol label, drug interactionsClinical Impact; Paricalcitol is partially metabolized by CYP3A. Hence, exposure of paricalcitol will increase upon coadministration with strong CYP3A inhibitors such as but not limited to: boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole.
Zemplar label (AbbVie Inc., August 1, 2024), drug interactionsExamples; Boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, and voriconazole
Paricalcitol label (West-Ward Pharmaceuticals Corp, December 12, 2018), drug interactionsDRUG INTERACTIONS Co-administration with strong CYP3A inhibitors (e.g. ketoconazole) increases paricalcitol blood levels.
Source: FDA drug label (Zemplar, NDA020819), AbbVie Inc., effective August 1, 2024 (SPL set 7259652f-81bc-4ad1-bba5-d01f9fac1b80), via openFDA
Source: FDA drug label (Paricalcitol, NDA207174), Accord Healthcare, Inc., effective July 30, 2024 (SPL set 2b7c7587-2042-0d9c-e054-00144ff88e88), via openFDA
Source: FDA drug label (Paricalcitol, NDA205917), West-Ward Pharmaceuticals Corp, effective December 12, 2018 (SPL set 4db985c4-3ba2-4967-898b-35af77f150de), via openFDA
Source: FDA drug label (Zemplar), AbbVie Inc., effective August 7, 2024 (SPL set 1b27c026-2d60-47b4-2a9c-ded1818f21b5), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ketoconazole | Paricalcitol | |
|---|---|---|
| Labeled for | Fungal infections | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.249 per gram 2% cream | $1.28 per capsule 1 mcg capsule |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once